Filtered By:
Specialty: Infectious Diseases
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 742 results found since Jan 2013.
Zika infection is caused by one virus serotype, NIH study finds
( NIH/National Institute of Allergy and Infectious Diseases ) Vaccination against a single strain of Zika virus should be sufficient to protect against genetically diverse strains of the virus, according to a study conducted by investigators from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health; Washington University in St. Louis; and Emory University in Atlanta.
Source: EurekAlert! - Infectious and Emerging Diseases - July 29, 2016 Category: Infectious Diseases Source Type: news
NIH begins testing investigational Zika vaccine in humans
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage study will evaluate the experimental vaccine's safety and ability to generate an immune system response in participants. At least 80 healthy volunteers ages 18-35 years at three study sites in the US are expected to participate. Scientists at NIAID's Vaccine Research Center developed the investigational vaccine earlier this year.
Source: EurekAlert! - Infectious and Emerging Diseases - August 3, 2016 Category: Infectious Diseases Source Type: news
NIH explores connection between Ebola survival and co-infection with malaria parasites
(NIH/National Institute of Allergy and Infectious Diseases) People infected with Ebola virus were 20 percent more likely to survive if they were co-infected with malaria-causing Plasmodium parasites, according to data collected at an Ebola diagnostic laboratory in Liberia in 2014-15. Moreover, greater numbers of Plasmodium parasites correlated with increased rates of Ebola survival, according to the new study. Scientists from the National Institute of Allergy and Infectious Diseases, part the National Institutes of Health, led the project.
Source: EurekAlert! - Infectious and Emerging Diseases - August 16, 2016 Category: Infectious Diseases Source Type: news
Old dog begging for new tricks: current practices and future directions in the diagnosis of delayed antimicrobial hypersensitivity
Purpose of review: Antimicrobials are a leading cause of severe T cell-mediated adverse drug reactions (ADRs). The purpose of this review is to address the current understanding of antimicrobial cross-reactivity and the ready availability of and evidence for in-vitro, in-vivo, and ex-vivo diagnostics for T cell-mediated ADRs.
Recent findings: Recent literature has evaluated the efficacy of traditional antibiotic allergy management, including patch testing, skin prick testing, intradermal testing, and oral challenge. Although patch and intradermal testing are specific for the diagnosis of immune-mediated ADRs, they suffer ...
Source: Current Opinion in Infectious Diseases - October 28, 2016 Category: Infectious Diseases Tags: ANTIMICROBIAL AGENTS: BACTERIAL/FUNGAL: Edited by Edited by Monica A. Slavin Source Type: research
NIAID-supported study examines vulnerability of gonorrhea to older antibiotic drug
(NIH/National Institute of Allergy and Infectious Diseases) A new clinical research study seeks to determine whether a rapid molecular diagnostic test can reliably identify gonorrhea infections that may be treated with a single dose of an older antibiotic, ciprofloxacin. The study will enroll up to 381 men and women diagnosed with untreated Neisseria gonorrhoeae. It is sponsored by the National Institute of Allergy and Infectious Diseases and is being conducted by the NIAID-funded Sexually Transmitted Infections Clinical Trials Group at four sites.
Source: EurekAlert! - Infectious and Emerging Diseases - November 17, 2016 Category: Infectious Diseases Source Type: news
NIAID-sponsored study to assess shorter-duration antibiotics in children
(NIH/National Institute of Allergy and Infectious Diseases) Physicians at five US medical centers are planning to enroll up to 400 children in a clinical trial to evaluate whether a shorter course of antibiotics -- five days instead of 10 -- is effective at treating community-acquired pneumonia in children who show improvement after the first few days of taking antibiotics. The National Institute of Allergy and Infectious Diseases, part of NIH, is sponsoring the clinical trial.
Source: EurekAlert! - Infectious and Emerging Diseases - November 28, 2016 Category: Infectious Diseases Source Type: news
NIH-supported scientists accelerate immune response to tuberculosis in mice
(NIH/National Institute of Allergy and Infectious Diseases) New research findings provide insight into the immune system pathways that may be key to developing an effective tuberculosis (TB) vaccine. The study, published today in the journal Nature Communications, was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - December 22, 2016 Category: Infectious Diseases Source Type: news
NIAID officials call for continued Zika research
(NIH/National Institute of Allergy and Infectious Diseases) Although cases of Zika virus infection appear to be decreasing, the mosquito-borne virus likely will become endemic in the Americas. Given the serious complications of Zika virus infection, researchers must continue their work to better understand how the virus causes disease and to develop effective vaccines and treatments, according to a new article, by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Disease (NIAID), and colleague Catharine I. Paules, M.D.
Source: EurekAlert! - Infectious and Emerging Diseases - January 13, 2017 Category: Infectious Diseases Source Type: news
NIAID flu experts examine evolution of avian influenza
(NIH/National Institute of Allergy and Infectious Diseases) In a new commentary published online in Emerging Infectious Diseases, two leading influenza experts from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, examine how the evolution of proteins found on the surfaces of flu viruses has impacted their ability to infect migratory birds and poultry and cause avian disease.
Source: EurekAlert! - Infectious and Emerging Diseases - January 18, 2017 Category: Infectious Diseases Source Type: news
Experimental malaria vaccine offers durable protection against many strains in NIH trial
(NIH/National Institute of Allergy and Infectious Diseases) An investigational malaria vaccine has protected a small number of healthy US adults from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy of Sciences (PNAS). The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored and co-conducted the Phase 1 clinical trial.
Source: EurekAlert! - Infectious and Emerging Diseases - February 21, 2017 Category: Infectious Diseases Source Type: news
NIH begins study of vaccine to protect against mosquito-borne diseases
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, has launched a Phase 1 clinical trial to test an investigational vaccine intended to provide broad protection against a range of mosquito-transmitted diseases, such as Zika, malaria, West Nile fever and dengue fever, and to hinder the ability of mosquitoes to transmit such infections. The study, conducted at the NIH Clinical Center in Bethesda, Maryland, will examine the vaccine's safety and ability to generate an immune response.
Source: EurekAlert! - Infectious and Emerging Diseases - February 21, 2017 Category: Infectious Diseases Source Type: news
Respiratory syncytial virus vaccine enters clinical testing
(NIH/National Institute of Allergy and Infectious Diseases) A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial also will assess the vaccine's ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.
Source: EurekAlert! - Infectious and Emerging Diseases - February 22, 2017 Category: Infectious Diseases Source Type: news
NIH-funded Antibacterial Resistance Leadership Group details progress, challenges
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases provided funding to establish an Antibacterial Resistance Leadership Group to develop, prioritize and implement a clinical research agenda to address the growing public health threat of antibiotic resistance. A new series of articles appearing in the March 15 issue of the journal Clinical Infectious Diseases details the group's progress and outlines its ongoing and future efforts.
Source: EurekAlert! - Infectious and Emerging Diseases - March 9, 2017 Category: Infectious Diseases Source Type: news
Pre-existing immunity to dengue virus shapes Zika-specific T cell response
(La Jolla Institute for Allergy and Immunology) Although Zika and dengue are considered different virus 'species,' they are so closely related that the immune system treats Zika just like another version of dengue, report researchers at La Jolla Institute for Allergy and Immunology. Their latest study, published in the March 13, 2017, advance online edition of Nature Microbiology, shows that pre-existing immunity to dengue virus modulates the magnitude and breadth of the immune system's T cell response to Zika.
Source: EurekAlert! - Infectious and Emerging Diseases - March 13, 2017 Category: Infectious Diseases Source Type: news
Immune molecule protects against Zika virus infection in animal models
(NIH/National Institute of Allergy and Infectious Diseases) A molecule naturally produced by the immune system protects mice and monkeys against Zika virus infection, an international team of researchers has found. Administering the molecule, called 25-hydroxycholesterol or 25HC, to pregnant mice reduced Zika virus infection in the fetal brain and protected against Zika-induced microcephaly. The work was supported in part by the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - March 14, 2017 Category: Infectious Diseases Source Type: news
